Edition:
United States

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

37.67USD
14 Dec 2018
Change (% chg)

$1.18 (+3.23%)
Prev Close
$36.49
Open
$36.16
Day's High
$38.43
Day's Low
$36.10
Volume
105,455
Avg. Vol
91,321
52-wk High
$44.26
52-wk Low
$16.51

Latest Key Developments (Source: Significant Developments)

Biohaven Prices Public Offering Of 3.36 Mln Common Shares At $37.25/Share
Wednesday, 12 Dec 2018 10:56pm EST 

Dec 13 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 3.36 MILLION COMMON SHARES PRICED AT $37.25PER SHARE.  Full Article

Biohaven Announces Formation Of Bioshin, A Wholly Owned Asia-Pacific Subsidiary
Wednesday, 28 Nov 2018 04:00pm EST 

Nov 28 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES FORMATION OF BIOSHIN, A WHOLLY OWNED ASIA-PACIFIC SUBSIDIARY.BIOHAVEN PHARMACEUTICAL HOLDING - FORMATION OF BIOSHIN TO DEVELOP, COMMERCIALIZE ITS MIGRAINE, NEUROLOGY PORTFOLIO IN CHINA, OTHER ASIA-PACIFIC MARKETS.BIOHAVEN PHARMACEUTICAL HOLDING - BIOSHIN PLANS TO SUBMIT FIRST INVESTIGATIONAL NEW DRUG APPLICATION TO CHINA FOOD & DRUG ADMINISTRATION BEFORE 2018 END.  Full Article

Biohaven Says Initial Clinical Trial Of BHV-3500 To Explore A Range Of Doses Using Intranasal Administration
Monday, 22 Oct 2018 03:00am EDT 

Oct 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RECEIVES AUTHORIZATION TO PROCEED FROM FDA AND DOSES FIRST SUBJECT WITH BHV-3500, THIRD-GENERATION, SMALL MOLECULE CGRP-RECEPTOR ANTAGONIST.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - NONCLINICAL PROOF-OF-CONCEPT WITH BHV-3500 HAS BEEN OBSERVED IN A PRIMATE ASSAY.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - INITIAL CLINICAL TRIAL OF BHV-3500 WILL EXPLORE A RANGE OF DOSES USING INTRANASAL ADMINISTRATION.  Full Article

Biohaven Acquires Option To License Biologic Investigational Agent UC1MT
Tuesday, 9 Oct 2018 03:00am EDT 

Oct 9 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::ACQUIRES OPTION TO LICENSE BIOLOGIC INVESTIGATIONAL AGENT FOR INFLAMMATORY AND AUTOIMMUNE DISEASES FROM THE UNIVERSITY OF CONNECTICUT.UNDER AGREEMENT, CO HAS OPTION TO ACQUIRE AN EXCLUSIVE, WORLDWIDE LICENSE TO UC1MT AND ITS UNDERLYING PATENTS.CO AND UNIVERSITY OF CONNECTICUT SIGNED SPONSORED RESEARCH AGREEMENT TO SUPPORT ONGOING EXPLORATION OF ROLE OF MT IN HUMAN DISEASE.  Full Article

Biohaven Licenses Novel Myeloperoxidase Inhibitor From Astrazeneca
Wednesday, 5 Sep 2018 03:00am EDT 

Sept 5 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN LICENSES NOVEL MYELOPEROXIDASE INHIBITOR FROM ASTRAZENECA.ENTERED AGREEMENT, THROUGH SUBSIDIARY. WITH ASTRAZENECA FOR DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO AZD3241, AN ORAL MPO INHIBITOR.UNDER TERMS OF AGREEMENT, ASTRAZENECA WILL RECEIVE UPFRONT CASH PAYMENT AND SHARES IN BIOHAVEN.ASTRAZENECA AGREED NOT TO PURSUE ADDITIONAL MPO INHIBITORS IT HAS IN EARLY STAGE CARDIOVASCULAR DEVELOPMENT FOR NEUROLOGIC DISEASES FOR 5 YEARS.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY- PLANS TO CONDUCT A PHASE 3 CLINICAL TRIAL OF AZD3241 CANDIDATE FOR TREATMENT OF MULTIPLE SYSTEM ATROPHY.  Full Article

Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients
Sunday, 22 Apr 2018 10:00pm EDT 

April 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES ROBUST CLINICAL DATA WITH SINGLE DOSE RIMEGEPANT THAT DEFINES ACUTE AND DURABLE BENEFITS TO PATIENTS.BIOHAVEN PHARMACEUTICAL HOLDING SAYS BROAD AND CLINICALLY IMPORTANT BENEFITS BEYOND INITIAL REGISTRATIONAL ENDPOINTS ARE NOW REPORTED..BIOHAVEN- RIMEGEPANT FIRST ORAL CGRP RECEPTOR ANTAGONIST TO DELIVER POSITIVE DATA ON PAIN FREEDOM IN TWO PIVOTAL PHASE 3 TRIALS IN ACUTE TREATMENT OF MIGRAINE.  Full Article

Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant
Monday, 26 Mar 2018 03:00am EDT 

March 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES SUCCESSFUL ACHIEVEMENT OF BOTH CO-PRIMARY REGULATORY ENDPOINTS IN TWO PIVOTAL PHASE 3 TRIALS OF RIMEGEPANT AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE.RESULTS ARE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL ACROSS MULTIPLE OUTCOME MEASURES.EFFICACY AND SAFETY RESULTS WERE CONSISTENT ACROSS BOTH PHASE 3 TRIALS..ON SCHEDULE TO SUBMIT AN NDA FOR RIMEGEPANT IN 2019​.  Full Article

Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Monday, 27 Nov 2017 03:00am EST 

Nov 27 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN COMPLETES ENROLLMENT IN SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL CGRP-RECEPTOR ANTAGONIST RIMEGEPANT.  Full Article

Biohaven Pharma qtrly loss per share $1.19‍​
Tuesday, 14 Nov 2017 06:02pm EST 

Nov 14 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven pharmaceuticals reports third quarter 2017 financial and business results.Biohaven pharmaceutical holding company ltd - qtrly loss per share $1.19‍​.  Full Article

Biohaven announces FDA clearance of IND application for sublingual BHV-0223
Wednesday, 1 Nov 2017 03:00am EDT 

Nov 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven announces FDA clearance of IND application for sublingual bhv-0223 in patients with amyotrophic lateral sclerosis (ALS).‍U.S. FDA has notified that co may proceed with clinical investigation of sublingual bhv-0223 ​.Expects to submit an IND to FDA by end of this year for BHV-3500 for treatment of migraine​.Expects to commence a Bioequivalence study of BHV-0223 in the current quarter.  Full Article